Trial of Buprenorphine/Naloxone for Opiate Dependence - 2

This study has been completed.
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000353
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: December 2002
  Purpose

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.


Condition Intervention Phase
Opioid-Related Disorders
Substance-Related Disorders
Drug: Buprenorphine/naloxone
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   19 Years to 57 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000353

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Charles O'Brien, M.D., Ph.D. PDVAMC Treatment Research Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000353     History of Changes
Other Study ID Numbers: NIDA-3-0012-2, Y01-3-0012-2
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Naloxone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Narcotic Antagonists

ClinicalTrials.gov processed this record on August 21, 2014